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Abstract: This study concentrates on the development of biodegradable nanofiber membranes 
with controlled drug release to ensure reduced tissue adhesion and accelerated healing. Nanofibers 
of poly(lactic-co-glycolic acid) (PLGA) loaded with epigallocatechin-3-O-gallate (EGCG), the 
most bioactive polyphenolic compound in green tea, were electrospun. The physicochemical 
and biomechanical properties of EGCG-releasing PLGA (E-PLGA) nanofiber membranes were 
characterized by atomic force microscopy, EGCG release and degradation profiles, and tensile 
testing. In vitro antioxidant activity and hemocompatibility were evaluated by measuring scav-
enged reactive oxygen species levels and activated partial thromboplastin time, respectively. 
In vivo antiadhesion efficacy was examined on the rat peritonea with a surgical incision. The 
average fiber diameter of E-PLGA membranes was approximately 300–500 nm, which was 
almost similar to that of pure PLGA equivalents. E-PLGA membranes showed sustained EGCG 
release mediated by controlled diffusion and PLGA degradation over 28 days. EGCG did not 
adversely affect the tensile strength of PLGA membranes, whereas it significantly decreased 
the elastic modulus and increased the strain at break. E-PLGA membranes were significantly 
effective in both scavenging reactive oxygen species and extending activated partial throm-
boplastin time. Macroscopic observation after 1 week of surgical treatment revealed that the 
antiadhesion efficacy of E-PLGA nanofiber membranes was significantly superior to those of 
untreated controls and pure PLGA equivalents, which was comparable to that of a commercial 
tissue-adhesion barrier. In conclusion, the E-PLGA hybrid nanofiber can be exploited to craft 
strategies for the prevention of postsurgical adhesions.
Keywords: nanofiber membrane, poly(lactic-co-glycolic acid), epigallocatechin-3-O-gallate, 
antiadhesion, tissue-adhesion barrier
Introduction
An adhesion develops as a result of the wound healing process, where tissue repair 
mechanisms respond to any disturbance, such as surgery, trauma, infection, or 
radiation.1–3 Postsurgical abdominal adhesions and their sequelae present major clinical 
and medicoeconomic problems such as small bowel obstruction, injury at reopera-
tions, female infertility, and chronic pain.4,5 Various types of barriers with the ability 
to reduce the adhesion formation are now available in the form of pharmacological 
and nonpharmacological agents, or a combination of these agents, applied between 
or over damaged tissue surfaces.6–8 Many different pharmacological agents, such as 
anti-inflammatory, fibrinolytic ,and antiproliferative drugs, have been used in an effort 
to arrest the adhesion pathway or to tip the balance in the favor of fibrinolysis and 
fibrin deposition.9 A number of pharmacological agents were approved for human 
use, some of which later had to be withdrawn from the market due to safety concerns 
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or lack of efficacy.10 Nonpharmacological antiadhesion 
agents can broadly be categorized into two types; one is a 
site-specific agent forming mechanical or gel barriers, such 
as membranes or films, fibrous sheets, and meshes, and 
another is a broad-coverage fluid agent, ie, instillates like 
lactated Ringer’s solution.9,10 A problem encountered with 
these agents is the necessity to decide intraoperatively where 
adhesions are likely to occur and, consequently, where to 
place the agents.6 The decision may be easy to make when 
there is only one injured site, but may be much more difficult 
in surgical patients with severe multiple injuries. Thus, an 
ideal agent should be easy to and ready to use and remain 
over injured surfaces for a limited period of time.
During the last few decades, considerable research 
has been conducted into the complex process of adhesion 
formation, and combined adhesion-prevention strategies 
have been investigated to develop optimal tissue-adhesion 
barriers. Hence, complete adhesion prevention remains an 
unsolved problem, and the search for an ideal antiadhesion 
agent is still ongoing. Thermosensitive hydrogels contain-
ing basic components of poly(ε-caprolactone, PCL) and 
poly(ethylene glycol, PEG) have been shown to effectively 
prevent postsurgical intra-abdominal adhesions.11,12 Moreover, 
nonwoven fibrous membranes, composed of biodegradable 
copolymers including poly(lactic-co-glycolic acid, PLGA), 
PLGA/PEG–poly(lactic acid, PLA) and polyurethane/PLGA, 
impregnated with antibiotic or anti-inflammatory drugs, have 
been examined previously in the context of adhesions in a rat 
model;13–15 however, their use in combination with green tea 
polyphenol, epigallocatechin-3-O-gallate (EGCG), is novel 
and challenging. The direct impregnation of PLGA nanofibers 
with EGCG has not been reported yet. Herein, we explore the 
potential of EGCG-releasing fibrous membranes as alternative 
agents to decrease the incidence of postoperative adhesions.
Materials and methods
Preparation of nanofiber membranes
PLGA (85:15 [mol/mol], molecular weight (MW) = 
130–150 kDa) resins were kindly supplied by BMG Inc. 
(Kyoto, Japan). EGCG-releasing PLGA (E-PLGA) nanofiber 
membranes were prepared by an electrospinning method. 
PLGA resins were dissolved in the solvent system consist-
ing of dichloromethane (Sigma-Aldrich Co., St Louis, MO, 
USA) and trifluoroethanol (Sigma-Aldrich Co.) with 8:2 ratio 
determined by optimization. The admixture (2, 4 and 8 wt%) 
of EGCG (MW =458.4, Teavigo™; DSM Nutritional Prod-
ucts Ltd., Basel, Switzerland) was obtained by dissolving it 
in hexafluoroisopropanol (Sigma-Aldrich Co.). The mixed 
solution of PLGA and EGCG was loaded in a 10 mL syringe 
equipped with a blunt 23-gauge needle. The electrospinning 
system consists of a syringe pump (single-syringe infusion 
pump; KD Scientific, Holliston, MA, USA) with a 10 mL 
syringe, a silicone hose, a stainless steel needle with an inner 
diameter of 0.8 mm, a high-voltage power supply (NanoNC, 
Seoul, Republic of Korea) and a thin aluminum foil acting as 
a collector, which was positioned horizontally and grounded. 
Under ambient conditions, the electrospinning process was 
performed to fabricate E-PLGA nanofibers loaded with 2, 
4, and 8 wt% EGCG (hereafter, E(2)-PLGA, E(4)-PLGA, 
and E(8)-PLGA, respectively). A positive voltage of 18 kV, 
a flow rate of 1 mL/hour, and a 12 cm distance between the 
needle tip and the collecting plate were used for this process. 
Following the spinning process, electrospun membranes were 
dried at room temperature for 6 hours and then placed at 50°C 
overnight. For physicochemical characterizations, prepared 
membranes were cut into discs of 12 mm in diameter and 
about 200 μM in thickness, which weighed approximately 
2.9 mg. Membranes for the in vitro bioactivity evaluation and 
in vivo animal study were prepared as sheets of 15×15 mm 
in dimension and about 5.8 mg in weight, with almost 
the same thickness as discs. Thus, approximately 230 μg 
(8 wt%, ≈500 μmol) and 460 μg (8 wt%, ≈1,000 μmol) 
EGCG were loaded in one E(8)-PLGA disc and sheet, respec-
tively. All discs and sheets made from E-PLGA nanofibers 
were sterilized by γ-irradiation (2.5 Mrad) prior to use.
Physicochemical characterizations  
of E-PLGA nanofiber membranes
Atomic force microscopy
The topography of PLGA and E-PLGA membranes was 
characterized by atomic force microscopy (AFM) (noncon-
tact mode, PSIA XE-100; PSIA Inc., Fremont, CA, USA) 
with a Multi 75 silicon scanning probe.
Raman spectroscopy
In order to confirm the dispersive loading of EGCG in 
E-PLGA membranes, Raman spectra of PLGA and E-PLGA 
membranes were obtained by Macro Probe Raman Measure-
ment System (Ramboss-500i; Dongwoo Optron Co., Ltd, 
Gwangju-si, Republic of Korea) equipped with a thermo-
electric-cooled charge-coupled device detector.
In vitro EGCG release from E-PLGA 
nanofiber membranes
E-PLGA discs were immobilized to the bottom of a glass 
vial by using sterile vacuum grease and then incubated 
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in Dulbecco’s phosphate-buffered saline (DPBS, pH 7.4; 
Sigma-Aldrich Co.) at 37°C for 28 days. At the end of each 
predetermined incubation period, the absorbance was quanti-
fied at 275 nm by an ultraviolet spectrophotometer (U-2800A; 
Hitachi Ltd., Tokyo, Japan). Cumulatively released EGCG 
from E-PLGA discs was calculated through the standard 
calibration curve of EGCG solution (Figure S1).
In vitro degradation of E-PLGA 
nanofiber membranes
Cumulative weight loss was used as an index of PLGA 
degradation in vitro. An initial weight of either PLGA or 
E-PLGA disc was weighed using an analytical balance 
(Ohaus Adventurer; Ohaus, Parsippany, NJ, USA). All 
weighed discs were immersed in 3 mL DPBS (pH 7.4) and 
incubated in a bioshaker (BR-4OLF; Taitec Corporation, 
Saitama, Japan) at 37°C with shaking at 60 rpm for up to 
8 weeks and medium was refreshed every week. The pH of 
the solution was monitored over time to ensure that a stable 
pH 7.4 was maintained at all times. At determined time inter-
vals, immersed discs were retrieved, washed with distilled 
water and dried in a vacuum desiccator for 24 hours at room 
temperature. Immediately after vacuum-drying, the weight 
of discs was measured by using the balance. The cumulative 
weight loss of PLGA and E-PLGA discs was determined as 
percentage (%) of the dry weight of each disc at each time 
divided by its initial dry weight.
Mechanical test
In order to evaluate the influence of EGCG blending on the 
mechanical properties of PLGA nanofiber membranes, the 
tensile strengths at break of PLGA and E-PLGA membranes 
were measured. The dimensions of all testing specimens 
were prepared according to the guidelines of the American 
Society for Testing and Materials (D-638 and D-882) for the 
uniaxial tensile strength testing.16 The tensile strength at break 
was determined using Autograph AG-20kNG (Shimadzu, 
Kyoto, Japan). A displacement of 1 mm/minute was applied 
to each specimen along with the longitudinal direction, and 
all data were collected at a frequency of 20 Hz until break 
occurred.
Reactive oxygen species levels by assay
The 2′,7′-dichlorodihydrofluorescein (DCF) assay is a 
widely used method to detect reactive oxygen species 
(ROS) levels in pharmacological studies.17,18 The amount 
of potential free radicals was quantified using an ROS 
assay kit (OxiSelect™; Cell Biolabs, Inc., San Diego, CA, 
USA), which employs the  cell-permeable fluorogenic probe 
2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA). 
DCFH-DA is an ROS detector that can cross cell mem-
branes and be deacetylated by intracellular esterases to 
nonfluorescent 2′,7′-dichlorodihydrofluorescein (DCFH). 
In the presence of ROS, DCFH is rapidly oxidized to the 
highly fluorescent DCF, which is readily detectable. The 
fluorescence intensity is proportional to the ROS levels 
within the cell cytosol.
For preparing the extracts of PLGA and E-PLGA 
nanofibers, each sheet was incubated for 3 days in DPBS 
(pH 7.4) at 37°C. L-929 cells (a murine fibroblast cell line, 
CCL-1; American Type Culture Collection, Manassas, VA, 
USA) were routinely maintained in a complete Dulbecco’s 
Modified Eagle’s Medium (Sigma-Aldrich Co.) supple-
mented with 10% fetal bovine serum (Sigma-Aldrich Co.) 
and 1% antibiotic antimycotic solution (including 10,000 U 
penicillin, 10 mg streptomycin, and 25 μg amphotericin B 
per mL; Sigma-Aldrich Co.) at 37°C in a humidified atmo-
sphere of 5% CO
2
 in air. Cells, grown to 70%–80% confluent 
monolayers, were pretreated with or without 50 μM H
2
O
2
 for 
30 minutes and then exposed to 50% diluted extract of either 
PLGA or E-PLGA sheet for 23 hours at 37°C in a CO
2
 incu-
bator. Afterwards, the cell cultures were further incubated 
with DCFH-DA for 30 minutes at 37°C in the dark. Parallel 
sets of wells containing vehicle-treated cells were regarded 
as the negative controls. The fluorescence emission of DCF 
was monitored at an excitation wavelength of 480 nm and 
an emission wavelength of 530 nm in a fluorescence plate 
reader (VICTOR3 Multilabel Counter; PerkinElmer, Inc., 
Waltham, MA, USA). The amount of DCF formed was 
calculated from a calibration curve constructed using an 
authentic DCF standard. The relative DCF fluorescence 
intensity was calculated as a percentage of the DCF formed 
in negative control wells.
Activated partial thromboplastin  
time measurement
The antithrombogenicity of E-PLGA nanofibers was evalu-
ated by determining activated partial thromboplastin time 
(aPTT). Citrated, platelet-poor plasma (PPP) was prepared 
from peripheral venous blood collected by clean, nontrau-
matic venipuncture directly into a polystyrene tube containing 
0.12 M trisodium citrate at a ratio of 9:1 and then centrifuged 
at 2,200× g for 10 minutes. The processed plasma was frozen 
and stored at -70°C. Immediately before testing, the PPP 
was thawed in a water bath at 37°C. According to the same 
process as described above, 50% diluted extracts in DPBS 
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(pH 7.4) of PLGA and E-PLGA sheets were prepared and 
then added to the thawed plasma. An aPTT reagent (APTT 
lyophilized silica, HemosIL™; Instrumentation Laboratory, 
Bedford, MA, USA) was used as follows: 0.1 mL of the 
reagent was mixed with the admixture of 0.1 mL PPP and 
diluted extracts and then incubated for 5 minutes at 37°C; 
and 0.1 mL of prewarmed calcium chloride (0.025 mol/L) 
was added and mixed, at which time the timer was started. 
Coagulation times (aPTT) were determined with a coagu-
lometer (IL ACL-300; Instrumentation Laboratory). Normal 
saline (0.9% NaCl) and heparin (0.1 U/mL) were employed 
as the negative and positive controls, respectively. Normal 
values of aPTT are reported as 24–37 seconds.19
Animal study for antiadhesion efficacy  
of E-PLGA nanofiber membranes
animals and experimental groups
Male adult (10-week-old) specific-pathogen-free Sprague 
Dawley rats (Samtaco Bio, Osan-si, Republic of Korea) 
weighing approximately 350 g each were individually housed 
in metabolic cages for 3 days before surgical treatment 
and until the day of sacrifice. They were given food and 
water ad libitum both preoperatively and postoperatively. 
All experiments were performed between the hours of 9 am 
and 5 pm. Animal care followed the criteria of the Animal 
Care Committee of Yonsei University College of Medicine 
for the care and use of laboratory animals in research. All 
experiments related to surgical procedures and treatments 
were performed in accordance with the guidelines of the 
Animal Experiment and Ethics Committee of Yonsei Uni-
versity College of Medicine. Rats were randomly divided 
into four experimental groups: Group I, rats treated without 
any antiadhesion agents (untreated controls); Group II, rats 
treated with pure PLGA membranes; Group III, rats treated 
with E(8)-PLGA membranes; and Group IV, as the positive 
control, rats treated with membranes of oxidized regenerated 
cellulose (Gynecare Interceed®; Ethicon Inc., Somerville, NJ, 
USA). Antiadhesion studies were carried out in 12 animals 
for each group.
surgical procedures and treatments  
for antiadhesion study
Sterile surgical technique was applied throughout the study. 
Animals were anesthetized by intraperitoneal injection with 
a mixture of 35–50 mg/kg ketamine HCl (Huons Co., Ltd., 
Seongnam-si, Republic of Korea) and 2% xylazine hydro-
chloride (Rompun®; Bayer AG, Leverkusen, Germany) 
before the celiotomy. After anesthetic induction, an area 
(about 15 cm2) in the skin of the abdomen was shaved 
and swabbed with alcohol and povidone iodine solutions. 
A longitudinal incision (5 cm long) was made using a blade 
(No. 11), and both abdominal walls (right and left side) were 
reflected and similar adhesion models were made on each 
of the abdominal walls. Abdominal walls were exposed and 
then a 10 mm ×10 mm of abdominal wall muscle away from 
the incision site was excised to exfoliate the peritonea until 
collagen was exposed, which formed small rectangles with 
roughly the same size. Tweezers were covered with gauze, 
and the outer surfaces of the internal organs exactly facing 
this defective abdominal wall area were abraded/brushed 
gently to trigger the adhesion process between these  defective 
surfaces. After that, one membrane (experi mental group) with 
a size of 15 mm × 15 mm was fixed with 6–prolene suture, 
at four corners on the right side of the abdominal wall, to 
cover the injured area. The left side of the abdominal wall 
was defective in a similar procedure, but left alone (ie, no 
membrane fixed), which served as control. Then, the middle 
line incision was closed using 4–0 silk suture. After 1 week, 
rats were euthanized and their abdominal cavities reopened 
by two other surgeons who were blind tested to evaluate 
the incidence and severity of postsurgical surgical adhesion 
based on adhesion score systems as described in Table 1. 
Table 1 Adhesion score systems for macroscopic evaluations
Adhesion scoring system Score Criteria
Extent of adhesions 0 No adhesion
1 1%–25% involvement
2 26%–50% involvement
3 51%–75% involvement
4 76%–100% involvement
Severity of adhesions 0 No adhesion
1 Tiny filmy adhesions easy to separate without tension or injury of the involved tissues
2 Dense adhesions that require tension to divide
3 Dense adhesions that lead to serosal injury during lysis or that need to be divided with scissors
4 Other intra-abdominal organs were involved, and a conglomerate was formed
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The adhesion score system was adopted according to each 
adhesion criterion: the extent of adhesion, following the cri-
teria of Leach et al20 and the severity of adhesion, following 
the criteria of Knightly et al.21 After scoring macroscopic 
adhesions, the adhesion site was excised enbloc with adhe-
sive tissues or organs and was fixed in 10% neutral buffered 
formalin for 24 hours, and segments were stained with 
hematoxylin and eosin. Microscopic grades for inflammation, 
neovascularization, fibrosis, and fatty infiltrate were graded 
from 0–3 as follows: 0, none; 1, mild; 2, moderate; and 3, 
dense, as previously described.22 The histopathologist who 
assessed each specimen was blinded to the information.
Statistical analysis
All variables were tested in three independent experiments 
in vitro, which was repeated twice (n=6). Quantitative data 
are expressed as mean ± standard deviation (SD). Data were 
tested for homogeneity of variances using the test of Levene, 
prior to statistical analysis. Statistical comparisons were car-
ried out with a one-way analysis of variance (ANOVA; SAS 
Institute Inc., Cary, NC, USA), which was followed by the 
Bonferroni test for multiple comparisons. Statistical analysis 
for the animal study was made by using the Kruskal–Wallis 
one-way ANOVA and Mann–Whitney U-test. A value of 
P0.05 was considered statistically significant.
Results and discussion
Physicochemical characteristics  
of E-PLGA nanofiber membranes
Electrospinning techniques can fabricate fibrous scaffolds 
with excellent biocompatibility and biodegradability, as 
well as suitable microstructure/nanostructure to guide tis-
sue regeneration and to incorporate bioactive molecules 
such as drugs, proteins, and genes.23–25 E-PLGA nanofiber 
membranes were prepared by electrospinning PLGA with 
2, 4, and 8 wt% EGCG and were seen to be slightly yel-
lowish red-colored due to loaded EGCG (Figure S2). The 
physicochemical properties of E-PLGA membranes were 
characterized by AFM, Raman spectroscopy, and EGCG 
release and degradation profiles. 
AFM demonstrated that E-PLGA membranes had a 
three-dimensional interconnected pore structure with ran-
domly oriented nanofibers (Figure 1A). The average fiber 
diameter of E-PLGA membranes was found to range between 
300–500 nm and to be almost similar to that of pure PLGA 
equivalents. Raman spectra of pure PLGA and E-PLGA 
membranes were dominated by the noticeable band near 
1,768 cm-1 (Figure 1B), which was due to the ester linkage 
of PLGA.26 The deformation band of CH
3
 was observed at 
1,450 cm-1, which corresponds to the antisymmetric vibration 
of CH
3
 from the lactic unit of PLGA.26 Also, quite intense and 
definite bands were found at 1,046 cm-1 and 1,127 cm-1 for the 
C-CH
3
 of PLGA. In E-PLGA membranes, the characteristic 
bands were found near 1,640 cm-1 and 3,450 cm-1, which are 
derived from the C=O and ring OH stretching vibrations of 
EGCG, respectively.27 This result indicates that EGCG was 
well dispersed in the E-PLGA fiber. 
The EGCG release profiles were examined to determine 
whether EGCG could be released from E-PLGA membranes 
in amounts necessary to generate effective concentrations 
that prevent postsurgical adhesions. As shown in Figure 1C, 
EGCG was released in a logarithmic manner in which the 
release rate decreased with time. A minor burst effect of less 
than 10% (50 μM) of loaded amounts was observed during 
the first day of release from E(8)-PLGA membranes. After 
7 days, E(8)-PLGA membranes showed the sustained release 
of EGCG. From the release profile, it was found that about 
180 μM and 240 μM (≈36% and 48% of loaded amounts) 
EGCG was cumulatively released from E-PLGA at 7 days 
and 28 days, respectively. In the cases of E(2)-PLGA and 
E(4)-PLGA membranes, the release patterns were similar 
to that of E(8)-PLGA membranes, whereas the cumula-
tively released concentrations (≈14% and 70 μM for E(2)-
PLGA membranes and ≈16% and 80 μM for E(4)-PLGA 
membranes) at 7 days were too low to reduce the adhesion 
formation. It is considered that the main release mechanism 
during the test period might be controlled diffusion of EGCG 
together with PLGA degradation.28
Figure 2A shows the cumulative weight loss of E-PLGA 
nanofiber membranes. The in vitro degradation profiles of 
E-PLGA membranes showed the stepwise patterns as fol-
lows. In the first step, for the period up to 1 week of incu-
bation, E-PLGA membranes exhibited a very fast weight 
loss rate (about 3% and 8% loss of the initial weight E(2 or 
4)-PLGA and E(8)-PLGA, respectively). After that period, 
the mass loss was decelerated until reaching the plateau at 
2 weeks or 4 weeks. In the second step, the degradation was 
reaccelerated and additional weight loss of more than 8% 
was observed in E(4)-PLGA and E(8)-PLGA membranes 
at 8 weeks. Different from that of E-PLGA membranes, the 
mass loss of pure PLGA equivalents was insignificant dur-
ing test periods. Aliphatic polyesters such as poly(glycolic 
acid), PLA, and PCL are known to be degraded by nonen-
zymatic random hydrolytic scission of esters linkage.29 The 
mass loss of E-PLGA membranes during incubation is 
considered to be more accelerated by the release of EGCG 
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Figure 1 Physicochemical properties of E-PLGA nanofiber membranes.
Notes: (A) AFM images, (B) raman spectra, and (C) in vitro release profiles of EGCG from E-PLGA membranes. All photographs shown in this figure are representative 
of six independent experiments with similar results.
Abbreviations: AFM, atomic force microscopy; au, arbitrary unit; EGCG, epigallocatechin-3-O-gallate; E-PLGA, EGCG-releasing PLGA; PLGA, poly(lactic-co-glycolic acid).
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from E-PLGA matrices. This E-PLGA degradation profile 
closely matches that of EGCG release and supports its 
release mechanism. 
The morphological changes of pure PLGA, E(2)-PLGA 
and E(8)-PLGA membranes during in vitro degradation 
are shown in Figures 2B–D. No significant morphological 
changes in pure PLGA membranes were observed at 2 weeks 
of incubation (Figure 2B). The small change in morphology 
during this period is also consistent with the small amount 
of shrinkage of the membrane. It was not until 8 weeks that 
the fibers started to break down into small pieces. However, 
the morphologies of E-PLGA membranes were significantly 
changed with the breakdown of the fibers into small pieces at 
the first week of incubation (Figures 2C and D). After 4 weeks, 
the degradation was more accelerated and most of the fibrous 
morphologies disappeared, with only chunks of degraded 
materials left. These phenomena can be explained by the fact 
that, due to unique nanofiber morphology with extremely high 
surface area to volume ratio, the water absorption capacity of 
 electrospun PLGA membranes is much larger than that of cast 
solid ( nonfibrous) films.30 These morphological observations 
agreed well with the quantitative degradation profiles.
Mechanical properties of E-PLGA 
nanofiber membranes
Biomechanical analysis revealed that EGCG did not alter 
the tensile strength of PLGA nanofiber membranes but 
substantially affected the elastic modulus (Em) of PLGA 
membranes (Figure 3). The Em of PLGA membranes was 
significantly (P0.05) decreased by EGCG blending, while 
their strain at break was significantly (P0.05) increased, 
suggesting that EGCG makes PLGA membranes less elastic 
but more plastic. This result was completely different from 
that observed with the cast solid film.16 Generally, the Em 
reflects elasticity, which tends to return the polymeric mate-
rial to its original form after deformation. Higher values of 
Em are associated with greater stiffness of the polymer. 
It is thus considered that upon EGCG addition, fibrous 
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Figure 2 Effects of EGCG blending on degradation of PLGA nanofiber membranes.
Notes: (A) In vitro degradation profile and scanning electron micrographs of (B) pure Plga, (C) E(2)-PLGA, and (D) E(8)-PLGA membranes.
Abbreviations: EGCG, epigallocatechin-3-O-gallate; E-PLGA, EGCG-releasing mag, magnification; PLGA; PLGA, poly(lactic-co-glycolic acid).
Figure 3 Mechanical properties of E-PLGA nanofiber membranes.
Notes: (A) Tensile strength, (B) elastic modulus, and (C) strain at break. Different letters denote significant differences between the control and experimental groups, 
P0.05. If two groups have the same single letter (a,b,c, etc), there is no significant difference between them. If a group is marked with a dual letter (eg, bc), it has significant 
difference from the control and another group marked with ‘a’, but does not from the other groups marked with ‘b’ or ‘c’.
Abbreviations: EGCG, epigallocatechin-3-O-gallate; E-PLGA, EGCG-releasing PLGA; PLGA, poly(lactic-co-glycolic acid).
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 membranes have the tendency to be tougher but less hard, 
which is directly opposite to nonfibrous ones.
In vitro antioxidant activity  
and hemocompatibility
In order to investigate whether EGCG released from E-PLGA 
is effective in scavenging ROS, a DCF assay was performed. 
Injury to the skin, eg, surgical incision or wounds, initiates a 
series of events including inflammation, new tissue forma-
tion, and matrix remodeling. During the early inflammatory 
phase, neutrophils and macrophages infiltrate the wounded 
tissue.31 Once activated, they produce large amounts of ROS 
as part of the host defense mechanism against bacterial 
and fungal infection. Although this process is beneficial, 
increased levels of ROS, eg, ⋅OH and H
2
O
2
, can inhibit cell 
migration and proliferation and can even cause severe tissue 
damage.32,33 For the detoxification of these molecules, cells 
synthesize various types of ROS-scavenging (ie, antioxi-
dant) enzymes. In addition, several studies have pointed to 
a role for ROS in postoperative adhesion formation,34 since 
the administration of ROS scavengers, such as catalase, 
superoxide dismutase, and trimetazidine, decreased adhe-
sion formation in several animal models.32,33 As shown in 
Figure 4A, both pure PLGA and E-PLGA nanofiber mem-
branes were shown to generate few, if any, ROS, but their 
ROS-scavenging ability was found to be very different from 
each other. It was revealed that the extract of E(8)-PLGA 
membranes significantly (P0.05) scavenged ROS derived 
from pretreated H
2
O
2
, which would adversely affect the 
cell viability, while that of pure PLGA equivalents did not 
exert any antioxidant activity. In the extract of E(4)-PLGA 
membranes, moderate effects were observed. From the 
release profile (Figure 1B), approximately 70 μM (≈14% of 
loaded amounts) EGCG was estimated to be released from 
E-PLGA membranes during the 3-day period. This result 
implies that released EGCG would play a pivotal role in 
detoxifying ROS.
Postsurgical adhesion formation is regulated by peri-
toneal fibrinolysis,35,36 which is determined by tissue-type 
plasminogen activator as a thrombolytic (or fibrinolytic) 
agent and plasminogen activator inhibitor-1.37 Suppression 
of inflammation, manipulation of coagulation, and direct 
augmentation of fibrinolytic activity may be promising 
antiadhesion treatment strategies.38 Thromboplastin, found 
especially in blood platelets, is a plasma protein that func-
tions in the conversion of prothrombin to thrombin in blood 
coagulation (or thrombogenesis). The aPTT test was widely 
used for the clinical detection of the abnormality of blood 
plasma and for the primary screening of the anticoagula-
tive chemicals.39 It was recently applied in the evaluation 
of the in vitro antithrombogenicity of biomaterials.40,41 The 
aPTT of pure PLGA and E-PLGA nanofiber membranes are 
presented in Figure 4B. The aPTT of E-PLGA membranes 
was significantly (P0.05) prolonged as compared to that 
of pure PLGA equivalents. E(4)-PLGA and E(8)-PLGA 
membranes showed about 57 seconds and 85 seconds of 
aPTT, respectively, which were 1.6–2.3 times longer than 
pure PLGA equivalents (≈32 seconds of aPTT). This result 
indicates that the activation of the intrinsic blood coagula-
tion system was suppressed by antithrombotic activities of 
EGCG released from E-PLGA nanofiber membranes.42 It was 
reported that phenolics such as catechin, epicatechin, querce-
tin, and resveratrol increased fibrinolytic protein (tissue-type 
plasminogen activator and urokinase-type plasminogen acti-
vator) expression and surface-localized fibrinolytic activity 
in cultured human umbilical-vein endothelial cells.43 Thus, 
adhesion barriers with the more effective fibrinolytic activity 
might be the better prophylactic strategy against unwanted 
fibrotic tissues.44,45
Macroscopic and microscopic evaluations 
on anti-adhesion efficacy of E-PLGA 
nanofiber membranes
During the study period, there was no mortality in any group. 
Gross adhesion findings and the distribution of adhesion 
scores among control and experimental groups are shown 
in Figures 5A and B, respectively. The average scores 
regarding the extent of adhesion were 3.60±0.55, 3.20±0.84, 
2.00±0.71, and 1.80±0.45 for Group I (untreated controls), 
Group II (pure PLGA membranes), Group III (E(8)-PLGA 
membranes) and Group IV (Interceed®, the positive control), 
respectively (Figure 5B). Pure PLGA membranes (Group II) 
showed a tendency toward slightly lower adhesion extent than 
the untreated controls (Group I), but there was no signifi-
cant difference between them. On the contrary, E(8)-PLGA 
membranes (Group III) had a significantly (P0.05) lower 
average adhesion extent score than pure PLGA equivalents, 
and the score was almost similar to that of the positive control 
(Interceed®). 
The average scores regarding the severity of adhesion were 
3.29±0.62, 3.14±0.81, 1.14±0.59, and 0.81±0.42 for Groups 
I–IV, respectively (Figure 5B). E(8)-PLGA membranes, but 
not pure PLGA equivalents, showed significantly (P0.05) 
less severe adhesion than untreated controls. The positive 
control also showed significantly (P0.05) lower adhesion 
severity scores than the other groups.  Representative images 
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Figure 4 In vitro bioactivity of E-PLGA nanofiber membranes.
Notes: (A) Antioxidant activity from scavenged ROS levels and (B) hemocompatibility from extended aPTT. Different letters denote significant differences between the 
control and experimental groups, P0.05.
Abbreviations: aPTT, activated partial thromboplastin time; DCF, 2′,7′-dichlorodihydrofluorescein assay; EGCG, epigallocatechin-3-O-gallate; E-PLGA, EGCG-releasing 
PLGA; PLGA, poly(lactic-co-glycolic acid); ROS, reactive oxygen species.
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for the most severe intra-abdominal adhesion in each group 
showed good agreement with the scores of the macroscopic 
adhesion (Figure 5A). Resultantly, E(8)-PLGA membranes 
showed significantly (P0.05) lower scores regarding both 
the extent and severity of adhesion than the untreated control 
and pure PLGA equivalents. However, no statistically sig-
nificant difference was found between the untreated control 
group and pure PLGA membranes. 
In terms of the extent and severity of adhesion, E(8)-PLGA 
membranes were found to have the potent ability to reduce 
abdominal adhesions, which was almost comparable to that 
of oxidized regenerated cellulose membranes (Interceed®). 
In previous randomized controlled trials, Interceed® has 
already been shown to have the efficacy and safety for pre-
venting postoperative abdominal adhesion;46,47 this potency 
was also confirmed in this study. In comparison to pure 
PLGA membranes, E(8)-PLGA membranes showed much 
better preventive effects of adhesion. 
Histopathological scores for inflammation, neovascular-
ization, and fibrosis from microscopic findings are shown in 
Figure 5C. Inflammation scores were 2.30±0.49, 2.50±0.50, 
0.70±0.35, and 0.90±0.49 for Groups I-IV, respectively. 
In particular, the E(8)-PLGA membrane (Group III) 
and Interceed® (Group IV) had significantly (P0.05) fewer 
inflammatory responses responses and neovascularization 
than the other groups. However, no significant difference was 
noted between the control group and pure PLGA membrane 
(Group II). Fibrosis scores were 2.60±0.36, 2.40±0.58, 
0.90±0.52, and 0.80±0.66 for Groups I-IV, respectively. 
The degree of fibrosis was minimal in E(8)-PLGA mem-
branes and Interceed®, whereas confluent fibrosis with acute 
inflammation was evident in the other groups. Resultantly, 
it was revealed that the prophylactic effect of E(8)-PLGA 
membranes on the abdominal adhesion was comparable to 
that of a commercial tissue-adhesion barrier, Interceed®. It 
is considered that EGCG released from E(8)-PLGA mem-
branes exerted potent anti-inflammatory and antifibrotic 
activity to suppress the adhesion formation. In other anti-
adhesion studies using drug-impregnated physical barriers, 
paclitaxel-loaded hyaluronic acid films and sirolimus-eluting 
polypropylene meshes were shown to effectively prevent 
postsurgical adhesions.48,49 Even if both paclitaxel and siroli-
mus are potent antiproliferative drugs, their major problems 
are the frequency of tissue toxicity and hypersensitivity 
reactions.50,51 On the contrary, green tea catechin is regulated 
as a “generally regarded as safe” compound by the US Food 
and Drug Administration, and concentrated green tea poly-
phenols are classified as dietary supplements.52
Conclusion
From in vitro studies, it is confirmed that EGCG sustainedly 
released from biodegradable E-PLGA nanofiber membranes 
plays a key role in scavenging ROS and extending aPTT. These 
findings support a scenario in which on postoperative week 1 in 
the abdominal adhesion model, macroscopic adhesion (extent 
and severity) scores of E-PLGA membranes are significantly 
lower than those of PLGA equivalents without EGCG; the 
levels are almost comparable to those of commercialized 
membrane-type barrier (Interceed®), which has already been 
shown to have efficacy and safety for preventing postopera-
tive abdominal adhesion. In conclusion, it is suggested that 
E-PLGA nanofiber membranes can safely reduce clinically 
relevant consequences of adhesions and may be effectively 
used in crafting strategies for the prevention of postsurgical 
adhesions without such problems as abdominal abscesses and 
anastomotic leaks, which may benefit patients.
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Figure S1 Standard calibration curve for the quantification of EGCG concentration.
Abbreviations: EGCG, epigallocatechin-3-O-gallate; OD, optical density.
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Figure S2 Digital photographic images of pure PLGA and E-PLGA membranes.
Abbreviations: EGCG, epigallocatechin-3-O-gallate; PLGA, poly(lactic-co-glycolic acid); E-PLGA, EGCG-releasing PLGA.
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